The chronic obstructive pulmonary disease (copd) and asthma devices market size has grown strongly in recent years. It will grow from $47.56 billion in 2025 to $50.3 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rising prevalence of asthma and COPD, increasing air pollution and smoking rates, growing use of inhalation therapy, expansion of respiratory care services, improved diagnosis of chronic respiratory diseases.
The chronic obstructive pulmonary disease (copd) and asthma devices market size is expected to see strong growth in the next few years. It will grow to $62.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to aging population with higher respiratory risk, rising demand for home care respiratory devices, increasing awareness of early respiratory disease management, expansion of chronic disease management programs, growing access to respiratory care in emerging markets. Major trends in the forecast period include rising adoption of home-based respiratory care devices, increasing demand for portable and user-friendly inhalation devices, growing focus on long-term disease management solutions, expansion of device usage across pediatric and geriatric populations, increasing emphasis on treatment adherence and symptom control.
The growing prevalence of respiratory diseases is expected to propel the growth of the chronic obstructive pulmonary disease (COPD) and asthma devices market going forward. Respiratory diseases encompass many conditions affecting the lungs and respiratory systems, such as asthma, chronic obstructive pulmonary disease, pneumonia, and lung cancer, impacting breathing and overall respiratory function. The growing prevalence of respiratory diseases is due to increasing air pollution levels, changing climate patterns affecting allergens and pathogens, and lifestyle habits such as smoking that compromise respiratory health. COPD and asthma devices play a crucial role in the comprehensive management and treatment of respiratory diseases, supporting patients to achieve better respiratory health and enhance their overall well-being. For example, in December 2023, according to the National Center for Biotechnology Information, a US-based government agency, the number of COPD cases was projected to increase by 112 million to reach approximately 592 million by 2050, accounting for about 9.5% of the eligible population. This rising prevalence of respiratory diseases is fueling growth in the COPD and asthma devices market.
Major companies operating in the chronic obstructive pulmonary disease and asthma devices market are concentrating on the development of innovative solutions such as smart, sensor-enabled inhaler technologies to improve medication adherence, enable real-time symptom monitoring, and support personalized respiratory disease management. Smart inhaler technologies integrate embedded sensors and digital connectivity to capture inhalation data, track patient usage patterns, and provide actionable insights to both patients and healthcare professionals. For example, in July 2023, Teva UK Ltd., a UK-based pharmaceutical company, launched GoResp Digihaler, a digitally connected inhaler designed to record inhalation parameters, deliver real-time feedback, and support improved disease control through data-driven patient engagement. The device contributes to better treatment outcomes by enabling remote monitoring, offering clinicians enhanced visibility into patient adherence patterns, and strengthening long-term disease management for individuals with chronic respiratory conditions.
In January 2025, Molex LLC, a US-based global electronics and connectivity solutions company, completed the acquisition of Vectura Group for an undisclosed amount. With this acquisition, Molex seeks to enhance its healthcare and medical device capabilities by incorporating Vectura’s advanced inhalation and drug-delivery technologies, thereby expanding its portfolio of connected, patient-centric respiratory solutions. Vectura Group is a UK-based pharmaceutical and medical device company that specializes in inhaled drug-delivery systems for COPD, asthma, and other respiratory conditions.
Major companies operating in the chronic obstructive pulmonary disease (copd) and asthma devices market are AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Boehringer Ingelheim, Royal Philips NV, Teva Pharmaceuticals Industries Ltd., Omron Corporation, Smiths Medical Inc., Cipla Ltd., Chiesi Farmaceutici SpA, Sunovion Pharmaceuticals Inc., Drive DeVilbiss Healthcare, Pari Respiratory Equipment Inc., Allied Healthcare Products Inc., Clement Clarke International Ltd., Cohero Health Inc., Pneuma Respiratory Inc., Mundipharma International Ltd., 3M Health Care, Vyaire Medical Inc., Aerogen Ltd.
North America was the largest region in the chronic obstructive pulmonary disease (COPD) and asthma devices market in 2025. The regions covered in the chronic obstructive pulmonary disease (copd) and asthma devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic obstructive pulmonary disease (copd) and asthma devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the COPD and asthma devices market by increasing costs for imported components such as plastics, electronic parts, and precision valves used in inhalers and nebulizers. These higher costs have impacted pricing for metered dose inhalers and nebulizer systems, particularly in asia-pacific and north america where global supply chains are heavily integrated. Increased tariffs have placed pressure on manufacturers and distributors supplying hospitals and home care settings. However, tariffs have also encouraged local manufacturing, alternative sourcing strategies, and cost-efficient device designs, supporting long-term supply chain resilience.
The chronic obstructive pulmonary disease (copd) and asthma devices market research report is one of a series of new reports that provides chronic obstructive pulmonary disease (copd) and asthma devices market statistics, including chronic obstructive pulmonary disease (copd) and asthma devices industry global market size, regional shares, competitors with a chronic obstructive pulmonary disease (copd) and asthma devices market share, detailed chronic obstructive pulmonary disease (copd) and asthma devices market segments, market trends and opportunities, and any further data you may need to thrive in the chronic obstructive pulmonary disease (copd) and asthma devices industry. This chronic obstructive pulmonary disease (copd) and asthma devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Devices for chronic obstructive pulmonary disease (COPD) and asthma are medical tools designed to manage and treat breathing and respiratory issues. These devices assist patients in breathing more efficiently, controlling symptoms, and enhancing their overall quality of life.
Key types of these devices include metered dose inhalers, dry powder inhalers, soft mist inhalers, jet nebulizers, ultrasonic nebulizers, and others. Metered Dose Inhalers are portable devices that administer medication in a precise spray or mist, commonly used for conditions such as COPD and asthma by delivering the medication directly into the lungs. They are small and easy to carry, making them suitable for everyday use. These devices are utilized in various settings such as hospitals, clinics, home care, and research facilities, and cater to different age groups including pediatric, adult, and geriatric patients.
The chronic obstructive pulmonary disease (COPD) and asthma devices market consists of sales of spacer devices, peak flow meters, oxygen therapy equipment, pulse oximeters, and airway clearance devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The chronic obstructive pulmonary disease (copd) and asthma devices market size is expected to see strong growth in the next few years. It will grow to $62.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to aging population with higher respiratory risk, rising demand for home care respiratory devices, increasing awareness of early respiratory disease management, expansion of chronic disease management programs, growing access to respiratory care in emerging markets. Major trends in the forecast period include rising adoption of home-based respiratory care devices, increasing demand for portable and user-friendly inhalation devices, growing focus on long-term disease management solutions, expansion of device usage across pediatric and geriatric populations, increasing emphasis on treatment adherence and symptom control.
The growing prevalence of respiratory diseases is expected to propel the growth of the chronic obstructive pulmonary disease (COPD) and asthma devices market going forward. Respiratory diseases encompass many conditions affecting the lungs and respiratory systems, such as asthma, chronic obstructive pulmonary disease, pneumonia, and lung cancer, impacting breathing and overall respiratory function. The growing prevalence of respiratory diseases is due to increasing air pollution levels, changing climate patterns affecting allergens and pathogens, and lifestyle habits such as smoking that compromise respiratory health. COPD and asthma devices play a crucial role in the comprehensive management and treatment of respiratory diseases, supporting patients to achieve better respiratory health and enhance their overall well-being. For example, in December 2023, according to the National Center for Biotechnology Information, a US-based government agency, the number of COPD cases was projected to increase by 112 million to reach approximately 592 million by 2050, accounting for about 9.5% of the eligible population. This rising prevalence of respiratory diseases is fueling growth in the COPD and asthma devices market.
Major companies operating in the chronic obstructive pulmonary disease and asthma devices market are concentrating on the development of innovative solutions such as smart, sensor-enabled inhaler technologies to improve medication adherence, enable real-time symptom monitoring, and support personalized respiratory disease management. Smart inhaler technologies integrate embedded sensors and digital connectivity to capture inhalation data, track patient usage patterns, and provide actionable insights to both patients and healthcare professionals. For example, in July 2023, Teva UK Ltd., a UK-based pharmaceutical company, launched GoResp Digihaler, a digitally connected inhaler designed to record inhalation parameters, deliver real-time feedback, and support improved disease control through data-driven patient engagement. The device contributes to better treatment outcomes by enabling remote monitoring, offering clinicians enhanced visibility into patient adherence patterns, and strengthening long-term disease management for individuals with chronic respiratory conditions.
In January 2025, Molex LLC, a US-based global electronics and connectivity solutions company, completed the acquisition of Vectura Group for an undisclosed amount. With this acquisition, Molex seeks to enhance its healthcare and medical device capabilities by incorporating Vectura’s advanced inhalation and drug-delivery technologies, thereby expanding its portfolio of connected, patient-centric respiratory solutions. Vectura Group is a UK-based pharmaceutical and medical device company that specializes in inhaled drug-delivery systems for COPD, asthma, and other respiratory conditions.
Major companies operating in the chronic obstructive pulmonary disease (copd) and asthma devices market are AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Boehringer Ingelheim, Royal Philips NV, Teva Pharmaceuticals Industries Ltd., Omron Corporation, Smiths Medical Inc., Cipla Ltd., Chiesi Farmaceutici SpA, Sunovion Pharmaceuticals Inc., Drive DeVilbiss Healthcare, Pari Respiratory Equipment Inc., Allied Healthcare Products Inc., Clement Clarke International Ltd., Cohero Health Inc., Pneuma Respiratory Inc., Mundipharma International Ltd., 3M Health Care, Vyaire Medical Inc., Aerogen Ltd.
North America was the largest region in the chronic obstructive pulmonary disease (COPD) and asthma devices market in 2025. The regions covered in the chronic obstructive pulmonary disease (copd) and asthma devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic obstructive pulmonary disease (copd) and asthma devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the COPD and asthma devices market by increasing costs for imported components such as plastics, electronic parts, and precision valves used in inhalers and nebulizers. These higher costs have impacted pricing for metered dose inhalers and nebulizer systems, particularly in asia-pacific and north america where global supply chains are heavily integrated. Increased tariffs have placed pressure on manufacturers and distributors supplying hospitals and home care settings. However, tariffs have also encouraged local manufacturing, alternative sourcing strategies, and cost-efficient device designs, supporting long-term supply chain resilience.
The chronic obstructive pulmonary disease (copd) and asthma devices market research report is one of a series of new reports that provides chronic obstructive pulmonary disease (copd) and asthma devices market statistics, including chronic obstructive pulmonary disease (copd) and asthma devices industry global market size, regional shares, competitors with a chronic obstructive pulmonary disease (copd) and asthma devices market share, detailed chronic obstructive pulmonary disease (copd) and asthma devices market segments, market trends and opportunities, and any further data you may need to thrive in the chronic obstructive pulmonary disease (copd) and asthma devices industry. This chronic obstructive pulmonary disease (copd) and asthma devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Devices for chronic obstructive pulmonary disease (COPD) and asthma are medical tools designed to manage and treat breathing and respiratory issues. These devices assist patients in breathing more efficiently, controlling symptoms, and enhancing their overall quality of life.
Key types of these devices include metered dose inhalers, dry powder inhalers, soft mist inhalers, jet nebulizers, ultrasonic nebulizers, and others. Metered Dose Inhalers are portable devices that administer medication in a precise spray or mist, commonly used for conditions such as COPD and asthma by delivering the medication directly into the lungs. They are small and easy to carry, making them suitable for everyday use. These devices are utilized in various settings such as hospitals, clinics, home care, and research facilities, and cater to different age groups including pediatric, adult, and geriatric patients.
The chronic obstructive pulmonary disease (COPD) and asthma devices market consists of sales of spacer devices, peak flow meters, oxygen therapy equipment, pulse oximeters, and airway clearance devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market Characteristics
3. Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market Supply Chain Analysis
4. Global Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market Trends and Strategies
5. Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market Analysis of End Use Industries
7. Global Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Total Addressable Market (TAM) Analysis for the Market
9. Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market Segmentation
10. Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market Regional and Country Analysis
11. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
12. China Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
13. India Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
14. Japan Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
15. Australia Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
16. Indonesia Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
17. South Korea Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
18. Taiwan Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
19. South East Asia Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
20. Western Europe Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
21. UK Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
22. Germany Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
23. France Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
24. Italy Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
25. Spain Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
26. Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
27. Russia Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
28. North America Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
29. USA Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
30. Canada Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
31. South America Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
32. Brazil Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
33. Middle East Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
34. Africa Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market
36. Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market Competitive Landscape and Company Profiles
37. Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market Other Major and Innovative Companies
40. Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses chronic obstructive pulmonary disease (copd) and asthma devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for chronic obstructive pulmonary disease (copd) and asthma devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chronic obstructive pulmonary disease (copd) and asthma devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Metered Dose Inhalers; Drug Powder Inhalers; Soft Mist Inhalers; Jet Nebulizers; Ultrasonic Nebulizers; Other Types2) By Indication: Asthma; Chronic Obstructive Pulmonary Disease
3) By Application: Hospitals; Clinics; Home Care Settings; Research Institutions; Other Applications
4) By End User: Pediatric; Adult; Geriatric
Subsegments:
1) By Metered Dose Inhalers: Conventional MDI; Breath-Actuated MDI2) By Drug Powder Inhalers: Dry Powder Inhalers (DPI); Multi-Dose DPI
3) By Soft Mist Inhalers: Respimat Soft Mist Inhalers; Other Soft Mist Devices
4) By Jet Nebulizers: Pneumatic Nebulizers; Venturi-Type Nebulizers
5) By Ultrasonic Nebulizers: Tabletop Ultrasonic Nebulizers; Portable Ultrasonic Nebulizers
6) By Other Types: Nebulizer Accessories; Spacer Devices
Companies Mentioned: AstraZeneca Plc; Novartis AG; GlaxoSmithKline Plc; Boehringer Ingelheim; Royal Philips NV; Teva Pharmaceuticals Industries Ltd.; Omron Corporation; Smiths Medical Inc.; Cipla Ltd.; Chiesi Farmaceutici SpA; Sunovion Pharmaceuticals Inc.; Drive DeVilbiss Healthcare; Pari Respiratory Equipment Inc.; Allied Healthcare Products Inc.; Clement Clarke International Ltd.; Cohero Health Inc.; Pneuma Respiratory Inc.; Mundipharma International Ltd.; 3M Health Care; Vyaire Medical Inc.; Aerogen Ltd
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices market report include:- AstraZeneca Plc
- Novartis AG
- GlaxoSmithKline Plc
- Boehringer Ingelheim
- Royal Philips NV
- Teva Pharmaceuticals Industries Ltd.
- Omron Corporation
- Smiths Medical Inc.
- Cipla Ltd.
- Chiesi Farmaceutici SpA
- Sunovion Pharmaceuticals Inc.
- Drive DeVilbiss Healthcare
- Pari Respiratory Equipment Inc.
- Allied Healthcare Products Inc.
- Clement Clarke International Ltd.
- Cohero Health Inc.
- Pneuma Respiratory Inc.
- Mundipharma International Ltd.
- 3M Health Care
- Vyaire Medical Inc.
- Aerogen Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 50.3 Billion |
| Forecasted Market Value ( USD | $ 62.83 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
